Oncology Medical News

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

Anti-CD20 Antibody Granted Accelerated Approval for CLL

Roberta Buell, MBA
Congress Proposes SGR Fix

Dorothy J. Schirf, MD

Technology Advances

Unique Catheter a Plus for Perfusion Therapy

Sara Hartley

Cancer Science

Using Embryonic Stem Cells to Test Breast Cancer Genes

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: A randomised phase 2 trial
The Lancet, 11/05/09

Andrés JM Ferreri et al. –Chemotherapy with high-dose methotrexate is the conventional approach to treat primary CNS lymphomas, but superiority of polychemotherapy compared with high-dose methotrexate alone is unproven. In patients aged 75 years and younger with primary CNS lymphoma, the addition of high-dose cytarabine to high-dose methotrexate provides improved outcome with acceptable toxicity compared with high-dose methotrexate alone. Patients aged 75 years and younger with primary CNS lymphoma, addition of high-dose cytarabine to high-dose methotrexate provides improved outcome with acceptable toxicity compared with high-dose methotrexate alone

Methods

Open, randomised, phase 2 trial
79 patients with non-Hodgkin lymphoma exclusively localised into the CNS, cranial nerves, or eyes, aged 18—75 years, and with Eastern Cooperative Oncology Group performance status of 3 or lower and measurable disease centrally randomly assigned by computer to receive 4 courses of either methotrexate 3·5 g/m2 on day 1 (n=40) or methotrexate 3·5 g/m2 on day 1 plus cytarabine 2 g/m2 twice a day on days 2—3 (n=39)
Both regimens administered every 3 weeks and followed by whole-brain irradiation
Primary endpoint was complete remission rate after chemotherapy
Analysis was by intention to treat

Results

Randomly assigned participants analysed
After chemotherapy, 7 patients given methotrexate and 18 given methotrexate plus cytarabine achieved a complete remission, with a complete remission rate of 18% (95% CI 6—30) and 46% (31—61), respectively
9 patients receiving methotrexate and 9 receiving methotrexate plus cytarabine achieved partial response, with ORR of 40% (25—55) and 69% (55—83), respectively
Grade 3—4 haematological toxicity was more common in methotrexate plus cytarabine group than in methotrexate group (36 [92%] vs six [15%])
4 patients died of toxic effects

<< Previous
Randomized phase III trial of gemcitabine-based chemotherapy with...

Next >>
Utility of the follicular lymphoma international prognostic index...